FDA Inspection 653973 — Celgene Corporation
The FDA completed an inspection of Celgene Corporation on Mar 19, 2010 in Summit, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 4 citations were issued during this inspection. Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 19, 2010
- Fiscal Year
- 2010
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Summit, NJ (United States)
Citations
| ID | CFR | Description |
|---|---|---|
| 1105 | 21 CFR 211.22(d) | Procedures not in writing, fully followed |
| 1942 | 21 CFR 211.180(e) | Records reviewed annually |
| 3572 | 21 CFR 211.100(b) | Procedure Deviations Recorded and Justified |
| 3616 | 21 CFR 211.165(d) | Acceptance criteria for sampling & testing |